[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H: Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer; 2008 May 15;112(10):2211-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
  • BACKGROUND: Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared.
  • Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary.
  • Response to platinum-based chemotherapy (PBC) overall survival, stage-for-stage median progression-free survival (PFS), and cause-specific median survival were compared.
  • RESULTS: Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013).
  • They presented more often with early disease (stage I and II; 50% vs 17%; P < .001), had less ascites, and had better performance status both overall and for stage II and III disease.
  • More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage.
  • Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001).
  • This relation remained for stage II and III disease and for moderately and poorly differentiated tumors.
  • Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone.
  • Independent predictors of survival after PBC were histological type, debulking status, and disease stage.
  • CONCLUSIONS: Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Organoplatinum Compounds / therapeutic use. Prospective Studies. Survival Rate


2. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer; 2004 May 10;109(6):926-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
  • We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian cancer patients.
  • Seventeen epithelial ovarian tumor specimens (13 malignant tumors, 5 at stage I, 2 at stage II, 6 at stage III; 2 borderline tumors; and 2 benign lesions) were available for pathologic evaluation.
  • Correlation between FDG uptake and clinical stage, GLUT-1 expression, MIB-1 LI and histologic grading score was determined.
  • No positive correlation was observed between FDG uptake and clinical stage (p=0.14).
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Biomarkers, Tumor. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radionuclide imaging. Cell Division. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Glucose / metabolism. Glucose Transporter Type 1. Humans. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027127.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Monosaccharide Transport Proteins; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


3. Aoki Y, Sato T, Watanabe M, Sasaki M, Tsuneki I, Tanaka K: Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. Gynecol Oncol; 2001 Jun;81(3):496-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma.
  • OBJECTIVE: The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma.
  • METHODS: Eleven patients were treated with preoperative neoadjuvant chemotherapy.
  • Those eligible included patients with previously untreated stage IB, II, or III adenocarcinoma with good performance status.
  • Treatment consisted of bilateral internal iliac artery infusion of cisplatin (a total of 10 mg/day) for 30 min, followed by 5-FU (a total of 250 mg/day) given by 24-hour continuous infusion for 10 days.
  • Treatment was repeated every 3 weeks for a total of two or three cycles.
  • All except one patient with progressive disease underwent radical hysterectomy following neoadjuvant chemotherapy.
  • Histopathological changes related to chemotherapy, however, revealed only mild effects.
  • Of the 24 treatment cycles administered, no Grade 3 or 4 toxicity was observed and there were no therapy-related deaths.
  • CONCLUSIONS: Intraarterial neoadjuvant chemotherapy effectively reduced tumor size in patients with locally advanced cervical adenocarcinoma; however, a survival advantage was not clear.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Hysterectomy. Infusions, Intra-Arterial. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging


Advertisement
4. Sorbe B: Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer; 2003 Nov-Dec;13 Suppl 2:192-5
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy.
  • In a prospective randomized trial, consolidation treatment with radiotherapy or chemotherapy was compared with no treatment in a series of 172 patients with epithelial ovarian carcinoma, FIGO stage III, with complete surgical remission after primary cytoreductive surgery and induction chemotherapy.
  • In the subgroup with complete pathological remission, progression-free survival (PFS) was significantly (P = 0.032) better in the radiotherapy group (56%) than in the chemotherapy group (36%) and the untreated control group (35%).
  • On the other hand, treatment-related side effects were more frequent in the radiotherapy group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / radiotherapy. Adenocarcinoma, Mucinous / surgery. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Papillary / surgery. Disease-Free Survival. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Neoplasm Metastasis. Norway. Prospective Studies. Second-Look Surgery. Sweden. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14656279.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Morice P, Joulie F, Rey A, Atallah D, Camatte S, Pautier P, Thoury A, Lhommé C, Duvillard P, Castaigne D: Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol; 2004;25(2):169-74
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy.
  • BACKGROUND: To report the rates of nodal involvement in epithelial ovarian cancer (EOC) in patients who underwent initial lymphadenectomy (before chemotherapy) and patients who underwent lymphadenectomy after chemotherapy.
  • STUDY DESIGN: The rates of nodal involvement in 205 patients with EOC who underwent complete bilateral pelvic and para-aortic lympadenectomy between 1985 and 2001 were analyzed: 100 women underwent this surgical procedure before chemotherapy (initial surgery) and 105 at the end of chemotherapy (second-look surgery for 77 patients with 6 courses of a platinum-based regimen) or during chemotherapy (interval debulking surgery for 28 patients with 3 courses of a platinum-based regimen containing paclitaxel).
  • In patients with Stage III disease, the rates of nodal involvement in patients treated with initial surgery, interval debulking surgery (with paclitaxel-based regimen) and second-look surgery were respectively: 53% (15/28), 58% (15/26) and 48% (20/42).
  • The rates of nodal involvement in patients who underwent lymphadenectomy prior to or after chemotherapy were not statistically different whatever the stage of the disease.
  • CONCLUSIONS: The rates of nodal involvement seem to be similar in patients treated before or after chemotherapy.
  • However, further studies are needed to evaluate the therapeutic value of lymphadenectomy in patients with nodal involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Drug Resistance, Neoplasm. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Second-Look Surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15032274.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Amikura T, Aoki Y, Kase H, Watanabe M, Sato T, Fujita K, Kurata H, Tanaka K: Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy. Int J Clin Oncol; 2002 Feb;7(1):45-50
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy.
  • BACKGROUND: The purpose of this study was to report the duration of the progression-free interval (PFI) in advanced ovarian cancer patients who were treated with intermittent maintenance chemotherapy.
  • METHODS: Between 1991 and 1998, 25 patients with stage III or IV ovarian cancer were enrolled in a trial of intermittent maintenance chemotherapy.
  • All patients underwent cytoreduction surgery, and received adjuvant chemotherapy, after which they were treated with intermittent maintenance chemotherapy every 3 to 4 months for 2 years.
  • RESULTS: The median PFI in the 25 women in the intermittent chemotherapy group was 25 months, while in the 32 patients in the control group it was 18 months (P = 0.0124).
  • The median survival of women treated with the intermittent chemotherapy was 34 months, and for the control group patients, it was 35 months (P = 0.0672).
  • Multivariate analysis in the intermittent chemotherapy group revealed that the only factor that correlated significantly with PFI was the status after adjuvant chemotherapy (P = 0.0137).
  • In patients with no evidence of disease after the adjuvant chemotherapy, the median survival was 39 months in the intermittent chemotherapy group, and 35 months in the control group (P = 0.0156).
  • The median PFI was 28 months in the intermittent chemotherapy group, and 18 months in the control group (P = 0.0012).
  • CONCLUSION: It would be warranted to perform intermittent maintenance chemotherapy for patients with advanced ovarian cancer, if a clinically disease-free status could be achieved after completion of the standard treatment procedure.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Mucinous / mortality. Adult. Aged. Antineoplastic Agents / administration & dosage. Carcinoma, Endometrioid / mortality. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystadenocarcinoma, Serous / mortality. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Japan / epidemiology. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11942049.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Vaidya AP, Littell R, Krasner C, Duska LR: Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:267-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
  • Uterine papillary serous carcinoma (UPSC) is more aggressive than endometrioid endometrial cancer, as it often presents with advanced disease and follows a pattern of spread that resembles the serous carcinoma of the ovary.
  • Charts were retrospectively evaluated from patients who had received at least three cycles of carboplatin and paclitaxel as first-line chemotherapy.
  • Only patients with histologically confirmed UPSC who were treated first line with carboplatin/paclitaxel chemotherapy were included.
  • Five patients were treated with consolidation radiotherapy following first-line chemotherapy.
  • The majority of patients had stage III disease (n= 11).
  • Fourteen patients achieved a complete response following chemotherapy.
  • The results of Gynecologic Oncology Group protocol 122 suggest that patients with advanced endometrial cancer have an improved progression-free survival when treated primarily with chemotherapy rather than radiation therapy.
  • The results of our study show a high response rate to paclitaxel/carboplatin outpatient chemotherapy in a group of patients historically believed to have chemoresistant disease.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Endometrial Neoplasms / drug therapy. Registries
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515602.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R, Japanese Gynecologic Oncology Group: Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol; 2008 Jan;108(1):226-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
  • OBJECTIVE: To establish an optimal adjuvant therapy for intermediate- and high-risk endometrial cancer patients, we conducted a multi-center randomized phase III trial of adjuvant pelvic radiation therapy (PRT) versus cyclophosphamide-doxorubicin-cisplatin (CAP) chemotherapy in women with endometrioid adenocarcinoma with deeper than 50% myometrial invasion.
  • The PRT group received at least 40 Gy.
  • These rates were also not significantly different in a low- to intermediate-risk group defined as stage IC patients under 70 years old with G1/2 endometrioid adenocarcinoma.
  • However, among 120 patients in a high- to intermediate-risk group defined as (1) stage IC in patients over 70 years old or with G3 endometrioid adenocarcinoma or (2) stage II or IIIA (positive cytology), the CAP group had a significantly higher PFS rate (83.8% vs. 66.2%, log-rank test P=0.024, hazard ratio 0.44) and higher OS rate (89.7% vs. 73.6%, log-rank test P=0.006, hazard ratio 0.24).
  • CONCLUSION: Adjuvant chemotherapy may be a useful alternative to radiotherapy for intermediate-risk endometrial cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Patient Compliance. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Treatment Outcome


9. Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL: The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol; 2000 Apr;77(1):55-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
  • PURPOSE: The aim of this study was to compare survival and recurrence in clinical and surgical stage I-II papillary serous (PS), clear cell (CC), and endometrioid (EM) cancers of the endometrium and examine the prognostic utility of myometrial invasion.
  • METHODS: Clinical, surgicopathologic, and survival data were retrospectively collected on 574 clinical stage I-II endometrial cancer patients, including 53 PS and 18 CC (based on postoperative histology), undergoing hysterectomy at Duke University Medical Center between 1967 and 1990.
  • Prognostic variables examined included age, stage, grade, myometrial invasion, lymph-vascular space invasion (LVSI), and histology.
  • Among PS, CC, and EM3 patients with recurrences there were no statistical differences in the proportion that received preoperative or postoperative radiotherapy or chemotherapy.
  • Prognostic factors for shorter survival included age >=60, surgical stage III+IV, presence of LVSI, histology (PS, CC, or EM3), and >=50% myometrial invasion.
  • PS + CC tumors confined to the endometrium had a 5-year survival of 0.60 compared to 0.98 and 1.00 for EM and EM3, respectively.
  • The 5-year survival for surgical stage I + II PS + CC patients (0.56) was comparable to that for clinical stage I + II PS + CC patients (0.46) and remained significantly smaller than that for EM patients (0.86) (P < 0.001).
  • When controlled for surgical stage I-II tumors, 5-year survival for PS + CC patients remains comparable to that of clinical stage I-II patients and below that of EM.
  • Prognostic factors for survival in PS and CC patients include age, stage, and LVSI.
  • Thorough extended surgical staging is indicated in PS and CC tumors, and prospective trials of aggressive adjuvant therapies for surgical stage I-II tumors are needed to improve outcome in PS and CC patients.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10739691.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Li J, Kong WM: [Prognostic factors of stage III endometrial carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jan 20;89(3):198-200

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of stage III endometrial carcinoma].
  • OBJECTIVE: To investigate the prognostic factors of surgery-pathological stage III endometrial cancer.
  • METHOD: The clinical data of 102 patients with stage III endometrial cancer, aged 54.9 (27-79), 71 with endometrioid adenocarcinoma, 31 with non-endometrioid adenocarcinoma, 9 undergoing simple surgical treatment, and 42 receiving radiation, 16 receiving chemotherapy, and 35 receiving chemoradiation after surgery, were analyzed retrospectively.
  • RESULTS: Cox risk model analysis showed that the risk factors for the prognosis of stage III endometrial cancer were pathological types, method of treatment, vascular thrombosis, and age (all P < 0.05).
  • The average survival time of stage III a endometrial cancer patients purely positive in peritoneal cytology was 74.4 months, significantly longer than that of the patients with serosa and/or annex involvement (53.8 months, P < 0.05).
  • CONCLUSION: The independent prognostic factors of stage III endometrial cancer are pathological type, method of treatment, vascular thrombosis, and age.
  • The patients with, the prognosis of stage III a endometrial cancer simply positive in peritoneal cytology is better than that with serous and/or annex involvement.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537039.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • Four hundred thirty-three patients with serous adenocarcinoma were used as controls.
  • RESULTS: Forty-five patients with mucinous invasive carcinoma were in FIGO I-II stages and 19 in III-IV stages.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Case-Control Studies. Female. Humans. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Morosky CM, O'Malley D, Tangir J, Zelkowitz RS, Azodi M, Chambers S, Schwartz P, Rutherford T: Carboplatin/Paclitaxel as adjuvant therapy for stage III endometrial adenocarcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin/Paclitaxel as adjuvant therapy for stage III endometrial adenocarcinoma.
  • : 5071 Background: The standard therapy for stage III endometrial adenocarcinoma (EAC) has been surgical staging followed by adjuvant radiation therapy.
  • Recent trials have suggested that platinum-based chemotherapy can also be used to manage advanced stage EAC.
  • This retrospective analysis evaluated the clinical outcomes of patients treated with adjuvant carboplatin/paclitaxel (carbo/taxol) therapy plus vaginal cuff radiation (VCR) for stage III EAC.
  • Thirty four patients were identified with stage III EAC.
  • Eleven patients (6=IIIa, 5=IIIc) had undergone carbo (AUC of 5) and taxol (175mg/m<sup>2</sup> over 3 hours) chemotherapy given every 3 weeks for 6 cycles along with VCR (total 1400-1500 cGy over 2-3 fractions) as adjuvant therapy.
  • All patients completed 6 cycles of chemotherapy.
  • Ten of eleven patients completed 6 cycles of carbo/taxol therapy.
  • Two patients required a dose reduction (one for grade III neutropenia, one for grade II arthralgia).
  • CONCLUSIONS: Adjuvant therapy with carbo/taxol plus VCR for stage III EAC is a well tolerated regimen with acceptable toxicities.
  • Systemic chemotherapy in addition to VCR may be a better tolerated adjuvant regimen with equal or improved efficacy when compared to radiation therapy based upon historical data.
  • Future prospective trials will need to compare the efficacy of carbo/taxol-based chemotherapies to radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015569.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Tominaga E, Tsuda H, Arao T, Nishimura S, Chiyoda T, Nomura H, Kataoka F, Susumu N, Aoki D, Nishio K: Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy.
  • : e16526 Background: The purpose of this study was to identify genes that predict the progression free survival (PFS) of advanced epithelial ovarian cancer (aEOC) receiving standard therapy.
  • Thirty three aEOC patients (stage IIc: 4, III: 19, IV: 10; serous adenocarcinoma: 21, endometrioid adenocarcinoma: 5, undifferentiated: 7) were included in this array study.
  • All cases received staging laparotomy, cytoreductive surgery, and adjuvant chemotherapy (carboplatin + paclitaxel) as primary therapy.
  • Finally, we focused on 8q24 and 20q11-13 loci, and confirmed array data using real-time quantitative PCR in 94 validation sets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.
  • RESULTS: 119 patients (stage I 92, II 11, III 15, and IV 1) were identified.
  • The OS for stage I and IIIC was 88% and 83%, respectively.
  • CONCLUSIONS: In patients with EEA, a tailored approach to LND and adjuvant therapy results in good outcome, but many still have therapy-associated adverse events.
  • Although no difference was found in OS between patients who underwent LND and those who did not, similar survival for patients with stages I and IIIC suggests that therapy directed by the knowledge of nodal status may have an impact on survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Miyagi E, Onose R, Ochiai K, Nozawa S, Noda K, Japan Multicenter Study Group: Phase II trial of paclitaxel in patients with adenocarcinoma of endometrium. J Clin Oncol; 2004 Jul 15;22(14_suppl):5121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of paclitaxel in patients with adenocarcinoma of endometrium.
  • : 5121 Background: The antitumor activity and safety of paclitaxel monotherapy in patients (pts) with endometrial cancer still remain to be clarified.
  • METHODS: Eligibility criteria included: advanced or recurrent histopathologically proven endometrial adenocarcinoma with measurable lesion(s), age between 20 and 75, ECOG PS 2 or less, adequate organ functions, and written informed consent.
  • No more than one regimen of prior chemotherapy was allowed.
  • Pts characteristics include: endometrioid adenocarcinoma (15), adenoacanthoma (2), serous adenocarcinoma (2), clear cell adenocarcinoma (2), adenosquamous carcinoma (1) and mixed adenocarcinoma (1), Stage III/Stage IV/Recurrent = 2/4/17, PS 0/1/2 = 14/7/2.
  • Thirteen pts had received prior chemotherapy.
  • All adverse reactions were successfully managed by prolonging treatment interval, dose reduction, interrupting administration, discontinuation, and/or administration of G-CSF.
  • Four pts discontinued treatment due to toxicity.
  • CONCLUSIONS: The results suggest that three-hour intravenous infusion of paclitaxel 210 mg/m2 is well-tolerated and active therapy for advanced or recurrent endometrial cancer, and is worthy of further study in combination with carboplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016767.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sakuragi N, Hareyama H, Todo Y, Yamada H, Yamamoto R, Fujino T, Sagawa T, Fujimoto S: Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand; 2000 Apr;79(4):311-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma.
  • BACKGROUND: The serous adenocarcinoma (SA) and clear cell adenocarcinoma (CCA) of endometrium have been shown to be associated with high relapse rate and poor survival.
  • It is not clear whether prognostic significance of these specific cell types of tumor is independent of retroperitoneal lymph node metastasis and other histopathologic prognostic factors in endometrial carcinoma.
  • METHODS: We examined 240 consecutive patients with clinical stage I to stage III endometrial carcinoma who were treated prospectively with radical surgery and/or platinum-based chemotherapy.
  • RESULTS: SA/CCA were more frequently associated with deep myometrial invasion, high nuclear grade (G3), lymph-vascular space invasion (LVSI), and pelvic lymph node metastasis when compared to endometrioid adenocarcinoma (EMA).
  • Of 216 clinically staged stage I or II disease, seven of 12 cases of SA/CCA had extrauterine disease.
  • A multivariate Cox regression analysis revealed that cell type, grade, LVSI, and paraaortic node metastasis (PANM) were independent prognosticators.
  • CONCLUSIONS: Prognosis of patients with endometrial carcinoma depends on cell type, grade, LVSI, and PANM.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10746848.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] DENMARK
  •  go-up   go-down


17. Irvin WP, Rice LW, Berkowitz RS: Advances in the management of endometrial adenocarcinoma. A review. J Reprod Med; 2002 Mar;47(3):173-89; discussion 189-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of endometrial adenocarcinoma. A review.
  • Endometrial adenocarcinoma is the most common and curable gynecologic neoplasm; the five-year survival for women with surgical stage I disease ranges from 83% to 93%; stage II, 73%; stage III, 52%; and stage IV, 27%.
  • The absence of an asymptomatic latency phase amenable to detection through screening and the already excellent cure rates seen with early-stage disease have precluded the need for endometrial cancer screening programs.
  • Adenocarcinomas constitute 97% of endometrial cancers, with endometrioid the most common histologic subtype.
  • Two different pathways of endometrial carcinogenesis exist.
  • One arises in a background of estrogen excess, giving rise to atypical hyperplasia as the malignant precursor of the more common endometrioid adenocarcinomas.
  • The use of oral contraceptives has consistently been shown to decrease the risk of developing endometrial carcinoma via this pathway, with 12 months or more of continuous use decreasing the lifetime risk by 40-50%.
  • The alternate pathway of endometrial carcinogenesis represents malignant transformation of atrophic endometrium and proceeds through endometrial intraepithelial carcinoma as the malignant precursor of the more virulent serous papillary and clear cell endometrial adenocarcinomas.
  • The staging of endometrial cancer (according to the International Federation of Obstetrics and Gynecology) is surgical.
  • Recent studies suggest a therapeutic benefit associated with extensive retroperitoneal lymph node evaluation to determine the disease extent and thereby more effectively direct potentially life-saving adjuvant therapy.
  • Adjuvant radiation therapy, known to have survival benefit in advanced-stage disease, may also have survival benefit in intermediate-risk surgical stage I disease on the basis of results recently released from a Gynecologic Oncology Group study.
  • The use of radiation therapy, systemic chemotherapy and hormonal therapy, alone or in combination, is recommended for primary advanced and recurrent disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Neoplasm Staging
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Incidence. Radiotherapy, Adjuvant. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11933681.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


18. Eltabbakh GH, Shamonki J, Mount SL: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol; 2005 Nov;99(2):309-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors.
  • OBJECTIVE: The purpose of our study was to assess the surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy showed well-differentiated (FIGO grade 1) carcinoma.
  • MATERIALS AND METHODS: A retrospective study was conducted including all women treated at the University of Vermont between 1992 and 2004 whose preoperative endometrial biopsy was reviewed by the staff at the Pathology Department and diagnosed as FIGO grade 1 adenocarcinoma and who received peritoneal washings, total abdominal (or laparoscopic) hysterectomy, bilateral salpingo-oophorectomy, and pelvic +/- para-aortic lymphadenectomy as part of their surgery.
  • Postoperatively, 131 (72%) patients received no additional treatment, 47 (25.8%) received radiation therapy, 3 (1.6%) received chemotherapy, and 1 (0.5%) received Megace.
  • CONCLUSIONS: Approximately 30% of women with endometrial carcinoma whose preoperative endometrial biopsy shows grade 1 tumors have grade 2 or 3 in the hysterectomy specimen and 12.6% have advanced surgical stage (stage III and IV) disease.
  • Women with preoperative endometrial biopsy showing grade 1 tumors who undergo surgical staging have excellent survival and acceptable operative morbidity.
  • [MeSH-major] Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cell Differentiation / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005945.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Obeidat B, Latimer J, Crawford R: Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest; 2004;57(3):153-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
  • The aim of this study was to determine the ability of preoperative serum CA-125 levels to predict optimal cytoreduction in patients with stage III epithelial ovarian cancer.
  • A retrospective review was made of the records of 40 patients with FIGO stage III ovarian carcinoma who underwent primary cytoreductive surgery.
  • In the management of patients with advanced epithelial ovarian carcinoma, preoperative serum CA-125 level may help to predict optimal primary cytoreduction and to identify candidates for alternative approaches other than traditional primary cytoreductive surgery, such as neoadjuvant chemotherapy.
  • [MeSH-major] CA-125 Antigen / blood. Ovarian Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / surgery. Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / surgery. Cystadenocarcinoma, Papillary / blood. Cystadenocarcinoma, Papillary / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Preoperative Care. Retrospective Studies. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14726621.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


20. Beshara N, Fung Kee Fung M, Faught W: The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. Eur J Gynaecol Oncol; 2002;23(4):287-90
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of topotecan as second-line therapy in patients with recurrent ovarian cancer.
  • INTRODUCTION: Up to 80% of patients with advanced ovarian cancer will recur following first-line platinum containing chemotherapy.
  • Topotecan has recently been used as a second-line agent in treatment of advanced ovarian disease.
  • The aim of the study was to evaluate the effect of topotecan on response rate and progression-free interval on patients with recurrent ovarian cancer who had been treated with platinum-containing first-line chemotherapy.
  • Response type was determined using World Health Organization (WHO) criteria.
  • Median age was 57 (range 41-80), 40/43 patients had stage III and IV, 37/43 patients had Grade 3 tumors.
  • Median time to response was eight weeks, median progression-free interval was 31 weeks and median time of follow-up and survival was 48 weeks.
  • CONCLUSION: Topotecan is considered a reasonable option for treatment of patients with recurrent ovarian cancer that have failed previous treatment with platinum-containing chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / mortality. Topotecan / administration & dosage
  • [MeSH-minor] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Mucinous / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / mortality. Cystadenocarcinoma, Papillary / mortality. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Medical Records. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214724.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


21. Bafghi A, Zafrani Y, Pautier P, Lhommé C, Duvillard P, Castaigne D, Haie-Meder C, Morice P: Endometrial disorders in patients with peritoneal serous papillary carcinoma. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):101-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial disorders in patients with peritoneal serous papillary carcinoma.
  • BACKGROUND: The purpose of this study was to evaluate the incidence rate of endometrial disease, particularly endometrial carcinoma, in patients with primary peritoneal serous papillary carcinoma (PSPC).
  • METHODS: Retrospective review of clinical and histological data from 32 women undergoing surgery (with hysterectomy) for stage III or IV PSPC.
  • RESULTS: Six patients underwent primary debulking surgery and 26 underwent interval debulking surgery after 3 or 4 courses of platinum-based chemotherapy.
  • Six patients (18%) had endometrial disease (hyperplasia in four).
  • Two patients had endometrioid adenocarcinoma of the uterine body (stage IA grade 1 in one case, and stage IB grade 1 in the other) associated with the PSPC.
  • CONCLUSIONS: Endometrial carcinoma of the uterine body may be associated with PSPC (6% cases in the present series).
  • This result suggests that systematic hysterectomy should be performed at the time of debulking surgery in PSPC, even in the absence of peritoneal spread within pelvic cavity.
  • [MeSH-major] Adenocarcinoma / complications. Cystadenocarcinoma, Serous / complications. Endometrial Hyperplasia / complications. Endometrial Neoplasms / complications. Peritoneal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860923.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


22. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • The most common symptoms were abnormal vaginal bleeding (69.8%) and abdominal or pelvic pain (44.2%).Pelvic masses were found in 39.5% of the patients and enlarged corpus in 27.9% at physical examination, while pelvic masses were found in 67.4% of the 43 patients (29 cases) and thickening or abnormal endometrium in 23.3% (10 cases) during ultrasound examination.
  • All 15 patients who underwent endometrial biopsies were proven to have endometrial carcinomas.
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


23. Tang L, Zheng M, Xiong Y, Ding H, Liu FY: [Clinical characteristics and prognosis of epithelial ovarian cancer in young women]. Ai Zheng; 2008 Sep;27(9):951-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was to evaluate the clinical characteristics, treatment, survival and prognosis of young patients with epithelial ovarian cancer.
  • Forty-four patients were classified as stage I (62.0%), five patients were stage II, 18 patients were stage III, and four patients were stage IV.
  • Serous adenocarcinoma (40 cases, 56.3%) and mucinous adenocarcinoma (22 cases, 30.9%) were the most common pathologic types.
  • Sixty-eight patients received platinum and paclitaxel-based chemotherapy before or after operation.
  • CONCLUSIONS: Young women with epithelial ovarian cancer under the age of 35 years mostly have serous adenocarcinoma; tumors are normally unilateral; and the prognosis is good.
  • The ovarian function can be preserved in part of stage Ia and Grade I patients.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Neoplasm Staging. Neoplasm, Residual / pathology. Ovariectomy. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Taxoids / therapeutic use. Tumor Burden. Young Adult


24. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group: Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat; 2008 Nov;112(1):99-108
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
  • Long-term tamoxifen users showed a higher proportion of non-endometrioid tumors than non-users (32.7% vs. 17.4%, P=0.004), especially serous adenocarcinomas and carcinosarcomas.
  • An increased proportion of FIGO stage III and IV tumors was also observed (20.0% vs. 11.3%, P=0.049).
  • Within FIGO stage I, both short-term and long-term tamoxifen users showed a higher proportion of tumors limited to the endometrium than non-users (35.7% vs. 22.9%, P=0.049 and 0.004 respectively).
  • Our results can be applied when weighing risks and benefits of tamoxifen versus other hormonal agents used in the prevention and treatment of breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / therapeutic use. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / mortality. Aged. Cohort Studies. Cystadenocarcinoma, Serous / chemically induced. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / mortality. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / mortality. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / diagnosis. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / chemically induced. Sarcoma / diagnosis. Sarcoma / mortality. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064567.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Visser O; Damhuis RA; Louwman WJ; van Dijck JA; Westerman Y; Dirx MJ; Jansen-Landheer ML; de Munck L; Siesling S
  •  go-up   go-down


25. Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I: Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma; 2009;56(4):291-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
  • Despite progress in primary treatment of patients with advanced ovarian cancer, the majority develop recurrence of the disease.
  • A platinum salt treatment, either as monotherapy or in combination with another cytostatic agent, is indicated for patients who have relapsed 6 or more months after primary treatment and thus have platinum-sensitive relapse.
  • Because repeated use of paclitaxel treatment may lead to substantial neurotoxicity, the combination of gemcitabine with carboplatin represents a suitable treatment option, which is widely used in common clinical practice in the Czech Republic and Slovakia.
  • This non-interventional, prospective study observed the effectiveness and tolerability of second-line treatment with gemcitabine and carboplatin in patients with platinum-sensitive relapse of ovarian cancer in routine clinical practice.
  • The primary endpoint was to evaluate the survival and secondary endpoints were to evaluate time to disease progression, objective tumor response rate, and treatment toxicity.
  • Patients were enrolled to planned second-line treatment with gemcitabine and carboplatin (gemcitabine 1000 mg/m2 and carboplatin AUC 5 on Day 1, and gemcitabine 1000 mg/m2 on Day 8 of a 21-day cycle) for platinum-sensitive relapse of ovarian cancer as a part of routine clinical practice and followed for 12 months.
  • Survival time (using Kaplan-Meier analysis) and objective tumor response rate were calculated using data forms, and a subgroup analysis was performed using log rank tests for time-to-event endpoints; p-values were also calculated.
  • Approximately 91% of patients were originally diagnosed with stage III or IV; 60% of patients had disease free intervals (DFIs) of 12 or more months from previous therapy, and the additional 40% less than 12 months.
  • Median survival time was not determined within the 12-month period following the start of the treatment study due to the limited duration of follow-up.
  • Most common reasons for discontinuation of therapy were "Planned treatment completed" (53%) and "Tumor progression" (11%).
  • Most common toxicities were leukopenia, anaemia, neutropenia, and thrombocytopenia; grades 3 and 4 of these toxicity types did not exceed 30%.
  • Results on time to disease progression are not published due to inconsistent statistical analysis of reported data.
  • Based on this observation from routine clinical practice, which corresponds with previously published results from controlled clinical trials, the gemcitabine and carboplatin combination seems to be a suitable therapeutic option for patients with platinum-sensitive relapse of ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473054.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


26. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • According to the International Federation of Gynecology and Obstetrics staging system, 4 cases were stage I tumors, 3 cases were stage III tumors, and 4 cases were stage IV tumors.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • Four of 5 patients who died of disease had either stage III or IV tumors and 3 of 5 patients who are alive without evidence of disease have stage I tumors.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


27. Pothuri B, Chi DS, Reid T, Aghajanian C, Venkatraman E, Alektiar K, Bilsky M, Barakat RR: Craniotomy for central nervous system metastases in epithelial ovarian carcinoma. Gynecol Oncol; 2002 Oct;87(1):133-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous series have reported various modalities for treatment with median survivals of 3 to 5 months, but the role of craniotomy has not been specifically addressed.
  • Distribution by stage and grade was as follows: Stage I, 0; II, 1; III, 12; and IV, 1; and grade 1,0; 2,4; and 3,10.
  • Histologic distribution was as follows: papillary serous, 9; endometrioid, 2; mixed papillary serous and endometrioid, 1; carcinosarcoma, 1; and poorly differentiated adenocarcinoma, 1.
  • All patients received initial platinum-based chemotherapy.
  • The median time from initial diagnosis of ovarian carcinoma to CNS relapse was 3.5 years (range, 1.3 to 8.2).
  • Eight patients (57%) had extracranial disease at the time of craniotomy.
  • The mean operative time for craniotomy was 178 min (range, 70 to 305).
  • The only major operative complications were deep vein thromboses that developed in two patients.
  • No patient developed a neurologic deficit as a result of craniotomy.
  • Postoperative treatment included whole-brain radiation in 11 patients, chemotherapy in 4, and hormonal therapy in 4.
  • CONCLUSIONS: Despite optimal cytoreduction, platinum-based chemotherapy, and negative second-look surgical assessment, patients with ovarian cancer can fail distantly with CNS metastases.
  • Craniotomy with adjuvant radiation therapy can provide control of brain metastases in the majority of these patients and may result in improved survival over radiation therapy alone in selected patients.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468354.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ: Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol; 2002 Apr;186(4):651-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrauterine progesterone treatment of early endometrial cancer.
  • OBJECTIVE: Our purpose was to assess the feasibility of using a progesterone-containing intrauterine device (IUD) to treat presumed Federation Internationale Gynecologie et d'Obstetrique (FIGO) stage IA, grade 1 endometrioid cancer in women at high risk for perioperative complications.
  • STUDY DESIGN: Candidates were women with American Society of Anesthesiologists class III or IV grade 1 endometrioid cancer and no imaging evidence of myometrial invasion.
  • Subjects underwent hysteroscopy, curettage, and IUD placement, followed by endometrial biopsy every 3 months for 1 year.
  • Fourteen consented to participation; one was excluded at the time of IUD placement (grade 2 disease identified) and one was lost to follow-up.
  • CONCLUSION: Intrauterine progesterone appears to eradicate some cases of presumed stage IA, grade 1 endometrioid cancer in women at high risk for perioperative morbidity.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Progesterone / administration & dosage. Uterus / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Biopsy. Curettage. Drug Administration Routes. Female. Humans. Hysteroscopy. Intrauterine Devices, Medicated. Magnetic Resonance Imaging. Menopause. Middle Aged. Neoplasm Invasiveness. Ultrasonography

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11967486.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


29. Adachi S, Itani Y, Ito K, Noda T, Shintani M, Saito K, Furukawa N, Tomii Y: Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer. Oncol Rep; 2001 Jan-Feb;8(1):27-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six of the patients who entered the study with stage IC and II disease are still alive with no evidence of disease.
  • The five-year survival rate was 61% for the 18 patients with stage III and IV disease; progression-free survival over 5 years was 32%.
  • Our results show this to be an effective treatment regimen for epithelial ovarian cancer.
  • Prognosis is good with this combined carboplatin/cisplatin/G-CSF therapy, especially for those patients with microscopic or no residual disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / mortality. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Hematologic Diseases / chemically induced. Hematologic Diseases / drug therapy. Hematologic Diseases / prevention & control. Humans. Infusions, Intravenous. Injections, Intraperitoneal. Japan / epidemiology. Life Tables. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11115564.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol; 2008 Sep;110(3):345-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Records of 62 patients with invasive EOC who underwent fertility-sparing surgery, defined as the preservation of ovarian tissue in one or both adnexa and the uterus, between May 1990 and October 2006, were retrospectively reviewed.
  • RESULTS: Of the 62 EOCs, 36 were stage IA, 2 were stage IB, 21 were stage IC, and 1 each was stage IIB, IIIA, and IIIC; 48 were grade I, 5 were grade II, and 9 were grade III.
  • Forty-eight patients received platinum-based adjuvant chemotherapy (mean 4.6 cycles, range 1-9 cycles).
  • Patients with stage >IC (p=0.0014) or grade III (p=0.0002) tumors had significantly poorer survival.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Disease-Free Survival. Female. Gynecologic Surgical Procedures / adverse effects. Gynecologic Surgical Procedures / methods. Humans. Neoplasm Invasiveness. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Mar;112(3):673-4; author reply 674 [18986689.001]
  • (PMID = 18586310.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement